Skip to content

Bristol-Myers Squibb

US · BMY #158 by market cap Listed 1970
58.80 +0.46 +0.79%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Barclays Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $75
    Market Newswire · 2026/11/16
  • New drug portfolio drives growth; Bristol-Myers Squibb (BMY.US) Q3 results beat expectations
    Zhitong Finance · 2026/10/29
  • Rating change
    A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $41 to $80
    Market Newswire · 2026/10/8
  • Rating change
    UBS Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $80
    Market Newswire · 2026/8/20
  • RBC Capital Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $64
    Market Newswire · 2026/10/28
  • Rating change
    Goldman Sachs Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $63
    Market Newswire · 2026/10/13
  • Rating change
    Bernstein Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating
    Market Newswire · 2026/8/21
  • Rating change
    A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $41 to $82
    Market Newswire · 2026/10/13
  • A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $64 to $75
    Market Newswire · 2026/10/30
  • Rating change
    Piper Sandler Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Cuts Target Price to $78
    Market Newswire · 2026/10/26
  • Rating change
    HSBC Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $65
    Market Newswire · 2026/9/10
  • Rating change
    A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $66 to $82
    Market Newswire · 2026/10/10
  • Rating change
    Wells Fargo Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $65
    Market Newswire · 2026/9/30
  • Rating change
    Goldman Sachs Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $63
    Market Newswire · 2026/10/20
  • Rating change
    Piper Sandler Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $78
    Market Newswire · 2026/10/27
  • Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Cuts Target Price to $40
    Market Newswire · 2026/10/30
  • Rating change
    Piper Sandler Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Raises Target Price to $82
    Market Newswire · 2026/9/16
  • Rating change
    A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $60 to $82
    Market Newswire · 2026/10/9
  • Rating change
    Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $40
    Market Newswire · 2026/9/25
  • Rating change
    Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Raises Target Price to $41
    Market Newswire · 2026/10/7
  • Barclays Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $75
    Market Newswire · 2026/10/29
  • Rating change
    Citi Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $70
    Market Newswire · 2026/8/14
  • Rating change
    Barclays Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $75
    Market Newswire · 2026/8/12
  • Rating change
    J.P. Morgan Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $73
    Market Newswire · 2026/8/5
  • Rating change
    Argus Research Upgrades Bristol-Myers Squibb(BMY.US) to Buy Rating, Announces Target Price $75
    Market Newswire · 2026/8/5

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.

Bristol-Myers Squibb discussion 0 comments

Add a comment